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ABSTRACT
When exogenous DNA is stably introduced in
mammalian cells, it is typically integrated in random
positions, and only a minor fraction enters a pathway
of homologous recombination (HR). The complex
Rad51/Rad52 is a major player in the management
of exogenous DNA in eukaryotic organisms and
plays a critical role in the choice of repair system. In
Saccharomyces cerevisiae, the pathway of choice
is HR, mediated by Rad52 (ScRad52), which differs
slightly from its human homologue. Here, we present
an approach that utilizes ScRad52 to enhance HR
in human cells containing a specific substrate for
recombination. Clones of HeLa cells were produced
expressing functional ScRad52. These cells showed
enhanced resistance to DNA damaging treatments
and revealed a different distribution of Rad51 foci
(a marker of recombination complex formation).
More significantly, ScRad52 expression resulted in
an up to 37-fold increase in gene targeting by HR.
In the same cells, random integration of exogenous
DNA was significantly reduced, consistent with
the view that HR and non-homologous end joining
are alternative competing pathways. Expression of
ScRad52 could offer a major improvement for
experiments requiring gene targeting by HR, both in
basic research and in gene therapy studies.
INTRODUCTION
Gene targeting by homologous recombination (HR) can be
used to stably replace a chromosomal sequence with an exo-
genous one (1). This technique would be useful both in gene
therapy, to correct a deﬁned sequence restoring the normal
function of a mutated gene, and in basic research, to introduce
speciﬁc mutations for experimental purposes. The generation
of speciﬁc gene knockout mice strains by manipulation of
mouse embryonic stem (ES) cells is the major example
of success of this technology (2). Somatic cells are less pro-
ﬁcient at gene targeting than ES cells, as targeting efﬁciency
in the former is prevented by non-homologous end joining
(NHEJ), which occurs at frequency 1000-fold higher than
HR (1,3).
Although very little is known on how cells choose the
recombination pathway to integrate an exogenous sequence,
a growing body of evidence indicates that HR and NHEJ
share some molecular components and can compete with
each other (3). When cells are transfected, plasmid DNA is
cleaved by cellular nucleases, producing free ends that mimic
DNA double-strand breaks (DSBs) (4,5). Free ends are
recognized and bound either by the Rad51/Rad52 complex
(eventually leading to HR), or by Ku70/Ku86 [HDF1 and
2 in yeast (6)], which in mammalian cells is more abundant
and results in NHEJ (7).
Several groups addressed the issue of targeting efﬁciency
in mammalian cells by modulating the expression of recomb-
ination proteins. In cells defective for the catalytic subunit
of DNA-dependent protein kinase (DNA-PKcs), involved in
NHEJ (8), gene targeting is increased, consistent with reports
that in the same cells expression of the missing protein
DNA-PKcs decreased spontaneous and induced HR (9). In
mammalian cells deﬁcient for Ku86 and Ku70, the rate of
HR was similar to that of control cells, arguing for a role
of DNA-PK complex downstream of the binding of Ku to
DNA free ends (8).
In other studies, overexpression of human Rad51 and Rad52
has been used as a means to promote HR. Conﬂicting results
have been obtained: in human ﬁbrosarcoma HT1080 and in
CHO cells, Rad51 overexpression increased the frequency
of HR by 2.2-fold, whereas human Rad52 overexpression
inhibited HR (10–12).
Recent experiments have demonstrated that the induction
of a DSB in the target sequence, achieved by constructing
a site-speciﬁc chimeric endonuclease, strongly increases the
frequency of gene targeting (13,14). Although the system is
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for every target gene constitutes a major limiting step.
We reasoned that the key to switch the balance towards
HR might be found in the Saccharomyces cerevisiae model,
where integration via HR mediated by the Rad52 epistasis
group is the default fate for exogenous DNA. Yeast strains
rad52 null are defective in HR, accumulate mutations and
chromosomal aberrations, and show increased sensitivity to
DNA damaging agents (15,16). The RAD52 gene product,
ScRad52, seems to be the essential factor for HR, as it can
promote DNA strand exchange, both dependent and inde-
pendent of Rad51 (17). This capacity is characteristic of the
yeast protein, whereas the mammalian homologous protein is
dispensable and necessarily depends on Rad51 interaction for
activity (18). Biochemically, the N-terminal DNA-binding
domainofthemammalianandyeastproteinsshare45%homo-
logy; the Rad51 interaction domain shares only 6% of amino
acid, and there is an uncharacterised C-terminal tract present
only in the yeast protein (19). Both proteins can promote
strand invasion in an in vitro assay, but the efﬁciency of
the yeast protein is almost 2-fold higher (20). These results
indicate that human and yeast Rad52 play different roles, and
that ScRad52 may contain additional functions promoting HR
instead of NHEJ.
Based on these data and on our previous observation that
yeast strains defective for Rad52 show a 10-fold reduction
in intrachromosomal recombination (16), we reasoned that
overexpression of the yeast Rad52 could possibly induce
an increase in the HR rate in human cells. To this purpose,
we derived several HeLaS3 clones expressing ScRad52 and
carrying a new genetic system, based on hygromycin
resistance (21), to detect gene targeting events.
The results conﬁrm that the expression of ScRad52 in
human cells signiﬁcantly increases the frequency of HR.
MATERIALS AND METHODS
Plasmid DNAs
The recombination plasmids were constructed from pTPSN
(from R. Michael Liskay, Oregon Health Science University,
Portland,OR), which containstwocopiesofhygromycinresis-
tance gene (hyg), one (hyg1) inactivated by an insertion of
10 bp generating a HindIII site at the unique PvuI site and
the other (hyg2) inactivated in the same way at the SacII site
(21,22). Plasmid pHygB
 Neo, the HR substrate with the hyg1
mutation, was obtained by pTPSN digestion with BamHI
and re-ligation (Figure 1). Plasmid pHygB
 , the targeting
construct with the hyg2 mutation, was made by cloning
the 2.2 kb BamHI fragment, containing the SacII insertion,
from plasmid pTPSN into the BamHI site of Litmus 28
(New England Biolabs).
The pMSGY52 plasmid containing the ScRad52 gene under
control of mouse mammarytumour virus long terminal repeats
was kindly provided by Colin Campbell, Minnesota Medical
School, Minneapolis, MN (23).
The plasmid pBlue-puro (a kind gift from R. Kanaar,
Erasmus University, Rotterdam, NL) contains the puromycin
resistance gene driven by cytomegalovirus promoter. It has
no homology with the genome of HeLaS3 cells; therefore, it
can integrate randomly.
Construction of cell strains
Plasmid pHygB
 Neo and plasmids pMSGY52–pHygB
 Neo
were transfected in HeLaS3 cells. Transfection by electro-
poration was carried out as follows: 3.5 · 10
6 cells were
suspended in 250 ml DMEM, without serum and antibiotics,
and mixed with 10 mg DNA (pMSGY52, pHygB
 Neo or
pHygB
 ). Cells were transferred to 1 ml cuvette (Equibio),
incubated for 10 min on ice, electroporated at 330 V/cm,
1000 mF and 200 W with Electroporator II (Invitrogen) con-
nected to a power supply (330 V, 25 mA, 25 W), incubated
again on ice for 10 min and seeded on 10 cm dishes in com-
plete medium. Transfection was considered successful when
cell survival approached 50%. G418 (1 mg/ml) was added
24 h later and resistant colonies were isolated and expanded.
Clones named HeLa.1B, HeLa.B2, HeLa.B5, HeLa.2A and
HeLa.4A were used in the experiments of HR.
Plasmid pMSGY52 was co-transfected with plasmid pBlue-
puro in clone HeLa.1B by electroporation. Cells were seeded
on 10 cm dishes in complete medium. Puromycin (0.2 mg/ml)
was added 24 h later and resistant colonies were isolated and
expanded. Clones named HeLa.1B-C and HeLa.1B-P were
used in the experiments of HR.
Detection of ScRad52 expression by RT–PCR
G418
R clones were characterized for ScRad52 expression by
RT–PCR. Total RNA from 2 · 10
6 cells was extracted with
RNeasy Mini KIT (Qiagen), quantiﬁed by ultraviolet (UV)
absorbance at 260 nm and treated with DNase I (Invitrogen).
An aliquot of 1 mg of total DNA-free RNA was reverse
transcribed using SuperscriptII  (Invitrogen) and subjected
to PCR. Ampliﬁcation of ScRad52 cDNA required a semi-
nested PCR to allow successful detection. In the ﬁrst round,
the forward primer 50-TTGCCAAGAACTGCTGAA-30 (S1)
and the reverse primer 50-GGAATATGCTTGGACGTA-30,
speciﬁc for ScRad52 (23), were used to amplify a region of
Figure1.GeneticsystemforthedetectionofHR.Intheupperpartofthefigure,
the top line represents the plasmid used to deliver the hyg1 defective gene to
thegenome.Itcontainsaselectablemarker(CMVneo)andhasa10bpinsertion
at the PvuI site of the hyg gene. The targeting DNA fragment hyg2 contains
the same insertion at the SacII site. An event of HR (represented by the two
couples of crossing lines) determines the restoration of an active hyg gene as
represented in the bottom line. Horizontal arrows indicate the primers used to
amplify a fragment of 359 bp which, after recombination, contains the PvuI
diagnostic site.
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subjected to a second round of PCR using primers S1 and
y1779 (50-CTTTATTACTGCTGTTTTTACTGTTAG-30)t o
amplify a region of 500 bp.
MMS assay, X-irradiation and short interfering RNA
ScRad52 expressing cells (3 · 10
3 cells/well) were seeded in
96 multi-wellplate. After 24 h, cells were incubated for60 min
with 1, 2 or 3 mM methyl methanesulfonate (MMS, Sigma).
Cell proliferation at various MMS concentrations was deter-
mined by the proliferating cell assay (Promega) at the end
of 1 h treatment and after 24 h. Values from the assay were
used to calculate the proliferation curve, using GraphPad
Prism v. 3.03.
For survival assay after X-irradiation, 200 cells were seeded
in 30 mm dishes and irradiated 36 h later at the doses of
1.25, 2.5, 5 and 7.5 Gy using a Siemens Stabilipan irradiator
(2 Gy/min, 18 mA and 200 kV). Cells were kept for further
10 days in culture and stained for colony counting.
ScRad52 was silenced using short interfering RNAs
(siRNAs) (24). Brieﬂy, a fragment of 700 bp located in the
coding region of the ScRad52 gene was ampliﬁed using pri-
mers 50-TCTGGTGGCCTTTGGTGTG-30 and 50-CTTTAT-
TACTGCTGTTTTTACTGTTAG-30, both preceded at 50 ends
by 23 nt (TAATACGACTCACTATAGGGAGA) encoding
the T7 RNA polymerase promoter to allow in vitro transcrip-
tion with the TurboScript T7 Transcription Kit (Gene Therapy
System). The double-stranded RNA obtained was treated
with recombinant Dicer enzyme to generate diced-siRNAs
(d-siRNAs) according to the manufacturer’s recommenda-
tions. Puriﬁcation was performed using d-siRNA Puriﬁcation
Columns and quantiﬁed by UV light absorbance. d-siRNAs
against enhanced green ﬂuorescent protein (EGFP) unrelated
gene were used as control. To silence ScRad52 gene, 4 · 10
5
expressing cells were seeded in 30 mm dishes and the day after
were transfected with 2 mg/dish d-siRNAs against ScRad52 or
EGFP using Gene Silencer reagent (Gene Therapy System).
After 24 h, cultures were trypsinized and seeded in 96 multi-
well plate for MMS experiment, or on cover-slips for the
Rad51 immuno-cytochemistry assay.
Determination of HR frequencies
HeLa.1B, HeLa.2A, HeLa.4A, HeLa.1B-C and HeLa.1B-P
clones were electroporated as described above with the
targeting plasmid pHygB
 , collected and seeded in complete
medium. After 24 h, hygromycin (300 mg/ml) was added to the
dishes. Selective medium was changed twice and after 15 days
dishes were stained with crystal violet and colonies counted.
The frequency of HR was calculated by dividing the total
number of hygromycin-resistant colonies by the number of
viable cells seeded. Cell viability was measured by scoring
the number of colonies formed after seeding 200 cells in
60 mm dishes in non-selective medium, followed by
7–10 days incubation.
To demonstrate the occurrence of HR, genomic DNA of
independent hygromycin-resistant clones was extracted and
puriﬁed. A 359 bp fragment surrounding the 10 bp linker
insertion at the PvuI site of the hyg1 mutant gene was ampli-
ﬁed by PCR with primers 50-TGATGCAGCTCTCGGAGG-30
and 50-AGTGTATTGACCGATTCCTTG-30. PCR products
were puriﬁed, checked for the presence of PvuI diagnostic
site by overnight digestion and analysed on a standard agarose
gel. The same PCR product was used for the sequencing of
selected clones.
Southern blot analysis was performed on DNA extracted
from parental and recombinant clones, according to the
standard procedures. Brieﬂy, DNA was extracted by ethanol
precipitation after Proteinase K treatment, resuspended over-
night in 1 M Tris–HCl, pH 8.0, and digested sequentially with
HindIII and BamHI. Digested DNA was separated on 0.8 %
agarose gel, blotted onto positively charged nylon membrane
and hybridized with Digoxigenin-labelled probe (Boehringer
Mannheim, DIG labelling kit). The probe fragment covers the
entire 2.2 kb hygromycin resistance gene.
Speciﬁc PCR to detect targeting events was performed
using a pair of primers speciﬁc for the recombination product:
primer 1 (50-GATCGGCCGCAGCGATCG-30) sits on the
PvuI site (CGATCG) and primer 2 was 50-TGATGCAGC-
TCTCGGAGG-30 in the Hyg coding region. The PCR was
performed using Taq polymerase (Invitrogen) that does not
have a 30!50 exonucleolytic activity.
Determination of non-homologous (random)
integration frequencies
Frequency of non-homologous integration was determined
by transfecting 2 mg of pBlue-puro vector in HeLa clones
(4 · 10
5 cells each) containing (HeLa.B2, HeLa.B5, HeLa.2A
and HeLa.4A) or not (Hela.1B) ScRad52. Transfections were
carried out with Polyfect transfectant (Qiagen) according to
the manufacturer’s recommendations. One day after transfec-
tion, cells were collected and plated (2 · 10
5 cells/dish) in
10 cm dishes containing 0.2 mg/ml puromycin. Culture med-
ium was changed after 7 days and replaced with puromycin-
free fresh medium. The colonies were stained and counted
7dayslater and the frequencyof recombinationwas calculated
by dividing the number of puro
R colonies by the number of
viable cells seeded.
X-ray treatment and visualization of Rad51 nuclear foci
X-ray treatment for immuno-histochemistry was performed as
follows: 4 · 10
5 cells were seeded in 30 mm dishes containing
two 12 mm round cover-glasses. Dishes were irradiated
(10 Gy) and after 6 h treated and control cells were ﬁxed
with paraformaldehyde 2% in phosphate-buffered saline
(PBS) for 15 min at room temperature.
Rad51 foci were detected following a protocol by Roland
Kanaar (25): cover-slips were washed with 0.1% Triton in
PBS, incubated for 1 h with rabbit anti-human Rad51 serum
(from R. Kanaar, Erasmus University, Rotterdam, NL) diluted
1:5000 in blocking buffer (0.15% glycine and 0.5% BSA in
PBS), washed again and incubated with secondary antibody
conjugated with Alexa-ﬂuor 594 (Molecular Probes).
RESULTS
Experimental system and characterization of the
ScRad52 expressing clones
The selection strategy developed to detect and quantify
recombination events is based on two DNA elements each
containinganinactive formofthegene conferringhygromycin
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 Neo (target gene)
contains, downstream of the Thymidine Kinase promoter,
a hyg gene with a 10 bp insertion in the PvuI site, together
with a neomycin phosphotransferase expression cassette
(CMVneo); individual cellular clones with the fragment inte-
gratedinthe genomeareobtainedthroughG418 selection.The
plasmid HygB
  (the targeting fragment) contains a hyg gene
with an intact PvuI site and a 10 bp insertion in a different
location. The linearized targeting plasmid is delivered to the
cells by electroporation. If a recombination event takes place,
the resulting chromosomal gene will be functional (allowing
for selection) and will contain the diagnostic PvuI site. This
transfection set-up represents the genetic system used to test
the hypothesis that ScRad52 affects the rate of HR.
HeLaS3 cells were transfected with pHygB
 Neo,
pMSGY52, or both, and several single cell clones were
selected and characterized. Using Southern blot analysis, one
copy of the hyg1 gene was found in clones HeLa.1B and
HeLa.2A, and three or more copies in clone HeLa.4A (data
not shown). Expression of the transgene was assessed on RNA
extracted from individual clones by RT–PCR (or PCR as
control, data not shown). All clones, except 1B, expressed
ScRad52 (Figure 2A). Observation of cell cycle distribution,
as measured by Propidium Iodide incorporation and FACS
analysis, showed no interference of ScRad52 with progression
of the cell cycle in all clones (data not shown).
The presence of ScRad52 in human cells can enhance the
efﬁciency of DNA repair after treatment with DNA damaging
agents (23,26,27), such as MMS. Therefore, we tested the rate
of cell proliferation after exposure to 1, 2 or 3 mM MMS
for 1 h. Figure 2B shows that all clones expressing ScRad52
were more resistant than the control clone. The possibility of a
non-speciﬁc effect due to the insertion of ScRad52 was ruled
out in the experiment shown in Figure 2C and D. The four
clones containing the transgene were pooled and ScRad52
expression was silenced using siRNA/DICER technology
(24). Figure 2C shows that ScRad52 RNA was reduced to
undetectable level, and Figure 2D reports that loss of Rad52
expression restores the original level of sensitivity to DNA
damage.
Further conﬁrmation of increased resistance of ScRad52
expressing cells to DSB was obtained by measuring cell
survival following X-irradiation. As shown in Figure 2E,
clones expressing ScRad52 show increased survival at all
X-ray tested doses.
Therefore, we have obtained a robust experimental set-up in
which it is possible to assess the role of a functional ScRad52
in a human genetic background.
Gene targeting is increased by ScRad52 expression
As described in the Introduction, when exogenous DNA is
transfected in human cells NHEJ occurs up to 1000 times
more efﬁciently than HR (4). To investigate whether the
expression of ScRad52 could enhance HR, we compared
ScRad52 positive and negative clones. Cells were electro-
porated with the hyg2 fragment and clones were selected
in medium supplemented with hygromycin as described in
Materials and Methods.
The results in Figure 3A show that in the ScRad52 express-
ing clone HeLa.2A, the frequency of HR was 15-fold higher
than in the control clone HeLa.1B. Interestingly, clone
HeLa.4A that contains more copies of the substrate showed
even higher (37-fold) gene targeting frequency. This repre-
sents a remarkable efﬁciency in this system, especially when
compared with the effect of the expression of other compo-
nents of the DNA repair pathway (see Discussion).
In cells with an inactive copy of the gene hyg1, resistance to
hygromycin can be acquired, under appropriate selection con-
ditions, by a spontaneous mechanism of gene rearrangement
in the absence of a targeting event. If a targeting fragment is
present, the resistant phenotype is more efﬁciently acquired
duetorecombinationvia gene targeting.Inoursystem,the two
possibilities can be resolved, because only in true recombi-
nants the hyg locus acquires PvuI sensitivity. Therefore, we
extracted genomic DNA from resistant clones and performed
a PCR followed by PvuI digestion as described in Materials
and Methods. In control cells (Figure 3B, HeLa.1B), three
clones out of the four are true recombinants, as demonstrated
by loss of the 359 bp band after digestion.
For analysis of cells expressing ScRad52, sub-clones
derived from clone HeLa.4A were selected because of the
higher recombination rate. The result of PCR and PvuI diges-
tion (Figure 3C) indicates that clones 2, 3, 4, 6 and 8 under-
wentgenetargeting,asconﬁrmedbythepresenceofthe289bp
fragment. However, DNA derived from these recombinant
clones was only partially digested; this suggests that only
one of the integrated substrates needs to be corrected to confer
hygromycin resistance. The PCR results (Figure 3C) indicate
that some of the clones acquire hygromycin resistance yet do
not appear to have PvuI-sensitive DNA (clones 5, 7 and 9). To
address this point, we also performed Southern blot analysis
on clones 2, 3, 5, 7 and 9, as shown in Figure 4. Genomic
DNA extracted from the parental and recombinant clones
was digested with BamHI, which cuts outside of the target
sequence hyg1, and with HindIII. The Hyg1 sequence inte-
grated in the genome is sensitive to HindIII, but after success-
ful targeting the HindIII site is replaced by PvuI site, and a
gene targeting event is revealed by the loss of HindIII site.
DNA from the parental clone HeLa.4A shows at least
six discrete bands, conﬁrming a minimum of three integrated
substrate fragments. All other clones show a lower number of
bands, which result from the loss of the HindIII site after HR.
Lack of PvuI sensitivity suggested in the PCR experiment
(Figure 3C) could be explained by the relative abundance
of uncorrected substrate and the ampliﬁcation dynamics of
PCR, which is strongly skewed towards the most represented
substrate. To further conﬁrm this point, we also performed a
PCR using a different primer (see Materials and Methods),
located over the PvuI site as illustrated in the scheme at the
bottom of Figure 4. DNA from all recombinant clones was
positive, indicating the presence of at least one HR product
(Figure 4B). The locations of the target sequence in HeLa.1B,
HeLa.2A and HeLa.4A clones are unlikely to be the same
since they represent different events of random integration,
which may undermine the clarity of results. We, therefore,
transfected ScRad52 into HeLa.1B, which already contains
the recombination substrate. Puromycin-resistant clones were
submitted to RT–PCR analysis to check the expression of
ScRad52 and to X-rays treatment to check their ability to
repair DSBs. Since two clones, HeLa.1B-C and HeLa.1B-P,
showed a transcriptionally active ScRad52 sequence
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(Figure 5B), they were used to detect the true contribution
of ScRad52 to HR. The results are reported in Table 1.
HeLa.1B-C and HeLa.1B-P clones showed a frequency of
HR that was 12- and 11-fold greater than control clone
HeLa.1B, thus demonstrating that the expression of ScRad52
is sufﬁcient to potentiate the gene targeting in human cells.
ScRad52 decreases NHEJ
In human cells, the introduction of exogenous DNA can mimic
an instance of DNA damage (4). The generally accepted
hypothesis argues that free DNA ends can be recruited by
proteins that belong to either of the two alternative pathways
leading to HR or NHEJ (3). To verify that the observed
Figure 2. Characterization of HeLaS3 clones expressing ScRad52. (A) Detection of ScRad52 expression by semi-nested RT–PCR. All selected clones, except
HeLa.1B, express the transgene. pMSGY52 DNA was used for PCR marker and GAPDH was used as RT–PCR control. (B) MMS sensitivity curves. Cells were
treatedfor1hwith1,2or3mMMMS,andproliferationwasmeasuredattheendoftreatmentandafter24h.Eachpointrepresentstheratiobetweenthemeasuresat
times 1 h and at 24 h and reports the mean value ± SD of six experiments. (C) Silencing of ScRad52 by d-siRNA. The pool of all ScRad52 expressing clones was
transfected with 2 mg of ScRad52/d-siRNA or EGFP/d-siRNA; RNA was extracted and used for RT–PCR as above. (D) MMS sensitivity in ScRad52 positive cells
transfected with d-siRNAs. The plot shows the relative cell proliferation after treatment with MMS. Each point represents the mean value ± SD of at least four
independent experiments; in some cases the SD is smaller than the printed symbol. (E) Cellular survival after X-irradiation. Cells were irradiated at the indicated
dosagesandcolonieswerestainedandcountedafter10days.Relativesurvivalwascalculatedbydividingthenumberofcoloniesbythenumberofseededcells.Each
point represents the mean value ± SD of three independent experiments performed in triplicate and is shown on a logarithmic scale.
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proteins rather than NHEJ, we measured the efﬁciency of
random integration in cells with or without ScRad52 expres-
sion. We transfected HeLa clones with pBlue-Puro plasmid.
The ScRad52 expressing clones HeLa.B2, HeLa.B5, HeLa.2A
and HeLa.4A showed a reduction in the number of resistant
clones obtained down to approximately one-third with respect
to the control clone HeLa.1B (Figure 6). This reduction was
signiﬁcant (P < 0.05) indicating that ScRad52 inhibited
random integration.
ScRad52 decreases Rad51 nuclear foci
It is well established that after DNA damage the endogenous
mammalian Rad51 protein, a major player in HR, re-locates in
distinct nuclear foci considered centres of molecular repair
(25,28,29). DNA-free ends are ﬁrst recognized by Rad51
together with its partner Rad52, leading to nuclear foci forma-
tion. These large multimolecular structures contain numerous
other proteins rather than Rad51 and Rad52, including Rad50,
Mre11, Nbs1 and PCNA. It has also been demonstrated
that Rad52 and Rad51 proteins physically interact in the
Figure 3. Effect of ScRad52 expression. (A) Frequency of HR. HR was
determined following electroporation of the hyg2 targeting plasmid and selec-
tion of hygromycin resistant colonies.Resultsare reported in logarithmicscale
as mean value ± SD of three independent experiments. Asterisks indicate that
the difference from the control is significant (P < 0.05). (B) DNA analysis
of clones recombined in the absence of ScRad52 (clone HeLa.1B). PCR was
performed on genomic DNA from single hygromycin-resistant colonies and
followedby PvuIdigestion.Thesizeofthe fragmentsis shownon theright.M,
100 bp marker; lane 1, false recombinant (PvuI resistant); lanes 2–4, true
recombinants (PvuI sensitive). (C) Analysis of clones derived from HeLa.4A.
M, 100bpmarker;lane1,non-digested PCRproduct;lanes2–9,PvuI-digested
PCR products. Note that undigested DNA is present even when recombination
has occurred, as shown by partial PvuI sensitivity.
Figure4.Molecularanalysisofhygromycin-resistantclones.(A)Southernblot
of recombinants. DNA from indicated clones was digested with HindIII and
BamHI to reveal the number of corrections on the integrated substrates (see
Figure 1). P, in the first lane, represents the parental clone HeLa.4A, which
showsatleastsixbands,resultingfromatleastthreecopiesofsubstrate.Clones
2 and 3 show half the number of bands, while clones 5, 7 and 9 (refractory to
PvuI digestion), >4 bands each, indicating that at least one copy was targeted.
(B) Recombination-specific PCR. DNA was subject to PCR using specific
primers able to anneal on the PvuI site, only available after correction, as
illustrated in the scheme. The expected PCR fragment of 306 bp was obtained
from recombinant clones, but not from the parental.
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metric complexes (30,31).
Recent reports, however, indicate that Rad52 (both human
and yeast) can initiate a strand exchange reaction in vitro in
the absence of Rad51 (20). If this is the case also in the
nuclear environment in vivo, it should be possible to observe
a different nuclear foci dynamics after DNA damaging
treatments in the presence or absence of exogenous Rad52.
Cells expressing ScRad52 and control cells were exposed to
X-rays (10 Gy) and ﬁxed after 6 h. Rad51 foci were identiﬁed
by indirect immuno-ﬂuorescence as shown in Figure 7A and
counted (Figure 7B). A reduction in the number of Rad51 foci
due to ScRad52 expression was evident in both exposed and
unexposed cells, indicating an effect of the protein prior to
DNA damage. This prompted us to investigate the number of
nuclear foci in each clone of cells expressing ScRad52 in the
absence of any treatment. Figure 7C reports the number of
Rad51 foci per nucleus: the reduction is signiﬁcant in each of
the expressing clones. To exclude the possibility of a general
decrease of Rad51 protein, we quantiﬁed the amount of Rad51
by western blot of cells expressing ScRad52. The results (data
not shown) demonstrated that the amount of protein was
comparable.
Silencing of ScRad52 by DICER/siRNA in clone HeLa.2A
and in the pool of all clones demonstrated that the effect is
speciﬁcally due to the presence of ScRad52, as shown in
Figure 7D.
Inpreviousstudies(29),it was observed thatoverexpression
of murine Rad52 in primary murine spleen cells induced an
increase in the number of Rad51 foci. The opposite effect that
we have obtained suggests that the yeast protein carries addi-
tional and/or different functions, as further discussed below.
DISCUSSION
Unlike mammalian cells, in S.cerevisiae DSB repair by HR is
strongly preferred over NHEJ (4,32). A major component of
the yeast recombination mechanism is Rad52 (15,19), which
is responsible for homologous pairing and strand exchange,
leading to the integration of an exogenous DNA fragment in
the target chromosomal locus. In vitro, the yeast protein has
been demonstrated to be more efﬁcient in the strand exchange
reaction than its human homologue, a property that could be
associated with additional domains present in ScRad52 (20).
To test whether the protein alone can enhance HR in mam-
malian cells, we developed a system to quantify HR in human
HeLa cells. A mutated hygromycin resistance gene (hyg1) was
ﬁrst inserted as single or multiple copies in the genomic DNA
of HeLa cells; in order to measure HR, these cells were then
transfected with a linear hyg2 fragment containing a different
Figure 5. Characterization of clones derived from HeLa1B and expressing
ScRad52. (A) Detection of ScRad52 expression by semi-nested RT–PCR. All
selected clones, except parental HeLa.1B, express the transgene. pMSGY52
DNA was used for PCR marker and GAPDH was used as RT–PCR control.
(B) Cell survival after X-irradiation. Cells were irradiated at the indicated
dosages and colonies were stained and counted after 10 days. Relative survival
was calculated by dividing the number of colonies by the number of seeded
cells. Each point represents the mean value ± SD of three independent experi-
ments performed in triplicate and is shown on a logarithmic scale.
Table 1. Effect of ScRad52 on HR frequencies (·10
 5 viable cells)
Clones Survival (%) hyg
R colonies n-Fold stimulation
HeLa.1B 65.3 ± 5.48 2.4 ± 1.2 1
Hela.1B-C 46.3 ± 15.32 29.0 ± 13.1* 12
HeLa.1B-P 49.0 ± 11.4 26.7 ± 8.6** 11
Results are reported as the mean of three or more experiments ± SD.
*P < 0.05;
**P < 0.01.
Figure 6. Effect of ScRad52 on non-homologous (random) integration. NHEJ
was measured after transfection of pBlue-Purovector and selection of colonies
by puromycin resistance as described in Materials and Methods. Results are
the mean value ± SD of four independent experiments. Asterisks indicate
significantdifferencesfromthecontrol(HeLa.1B)(P < 0.05),calculatedwith
Student’s t-test.
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 5viable
cells, in agreement with HR frequency of other cell lines
ranging from 10
 5 to 10
 7. Therefore, the system is a reliable
tool to measure HR in human cells and is suitable to evaluate
the effect of ScRad52 and other proteins of interest.
HR in cells is dependent on the interaction of several fac-
tors: the amount of target, which in natural condition would
be one or two copies (for dominant and recessive characters,
respectively), the amount of targeting construct delivered, the
efﬁciency of the HR machinery and other factors, such as
homology length (33,34) and cell cycle phase (35,36). In
the HeLa system used in this study, we only addressed the
effect of the presence of a single factor, namely ScRad52. To
this end, we considered both a clone with one substrate only
(HeLa.2A) and a clone with multiple copies (HeLa.4A).
We ﬁrst tested the effect of ScRad52 on survival after both
MMS and X-ray-induced damage, and show that its presence
induces a more efﬁcient recovery. This is consistent with the
results by Johnson et al., (23), who also observed a higher
efﬁciency of interplasmidic recombination upon overexpres-
sion of ScRad52 in human ﬁbroblasts.
In all clones expressing ScRad52, the frequency of HR was
between 11- and 37-fold the frequency of control cells as
shown in Figures 3 and 4 and Table 1. The Southern blot
analysis demonstrated that even in clones apparently negative
in the PCR/PvuI digestion assay (Figure 3C), at least one copy
of substrate is converted by HR (Figure 4A). A further con-
ﬁrmation of the correction was obtained by speciﬁc PCR in
Figure 4B. Therefore, ScRad52 induce a genuine increase
of HR. This represents a very remarkable effect, particularly
when compared with the 2- to 3-fold stimulation obtained by
overexpression of human Rad51 in human cells (12).
In order to assess the effect on NHEJ, we used a construct
with no sequence homology with chromosomal DNA. When
cells expressing ScRad52 were tested for random integration
efﬁciency, we found that they had an NHEJ frequency reduced
to one-third relative to the control line, supporting the
hypothesis that ScRad52 interferes with NHEJ and actively
Figure 7. EffectofScRad52onRad51nuclearfociinnegativeandpositiveclones.(A)EffectofScRad52onX-ray-inducedRad51nuclearfoci.Rad51nuclearfoci
weredetectedbyimmuno-fluorescencebefore(top)andafter(bottom)X-rayexposureincellsexpressing(right)ornot(left)ScRad52.(B)QuantificationofRad51
focipernucleusbeforeandafterX-rayexposure.Fociof50nucleiperclonewerecountedandarerepresentedasmeanvalue ± SDofthreeindependentexperiments:
cells expressing yeast Rad52 (grey bars) have a reduced number of foci, both before (left) and after (right) X-ray treatment. (C) Number of Rad51 foci in single
ScRad52 expressing clones. Spontaneous Rad51 nuclear foci were counted after immuno-cytochemistry in negative and positive clones. Results are reported as
the mean ± SD of five experiments. Asterisks indicate significant differences from the control (HeLa.1B) (P < 0.05). (D) Silencing of the transgene restores
thespontaneousnumberofRad51foci.Cells[poolofallclones(left)orsingleclone(right)]weretransfected(whitebars)withd-siRNAtosilenceexogenousRad52,
and foci were counted after immuno-staining. Treated cells show a number of foci comparable with wild type.
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inwhichScRad52 binds the free DNA ends, and inthe absence
of homology keeps them from recruiting components of the
NHEJ pathway. In this view, our data represent a further
support for the interactive competition model as discussed
below.
The analysis of Rad51 nuclear foci formation added insights
into ScRad52 function. Surprisingly, in cells expressing
ScRad52, the number of Rad51 foci was reduced (but not the
protein amount), yet DNA repair was not affected, as indicated
in results shown in Figure 2. This suggests that ScRad52 per-
forms HR more efﬁciently, despite the displacement of Rad51
and that ScRad52 could work in a Rad51-independent way
establishing a yeast-like nuclear dynamics in human cells.
The leading view of recombination proposes that the two
pathways, homologous and non-homologous, while sharing
some components, diverge and compete with one another (3).
The effort to increase the relative efﬁciency of HR has seen
several groups engaged in studies of overexpression and
repression of proteins involved in recombination and DSB
repair.
For example, Kim et al. (10) overexpressed human Rad51
and Rad52 in human and hamster cells to ﬁnd out that the two
genes, singly or in combination, caused a reduction, rather
than an increase, of the frequency of intrachromosomal HR
after DSB. Signiﬁcant inhibition of gene targeting in HT1080
human ﬁbroblasts after overexpression of human Rad52 pro-
tein was also reported by Yanez and Porter (11), who found
that in their system, random integration was slightly increased.
In contrast, the expression of ScRad52 in human cells induced
a 12-fold increase in inter-plasmid HR (23). In a study invol-
ving Rad52 from the yeast Kluyveromyces lactis, Milne and
Weaver (40) show that its overexpression in a RAD52 wt
strain of S.cerevisiae confers a dominant negative phenotype,
probably due to the strict homology among the two proteins,
which would interact in a less active hybrid form. From our
data, it seems likely that interaction among the human and
yeast proteins either does not occur (due to the very low
homology), or is overwhelmed by the large amount of the
exogenous protein produced.
From the literature and our data, we conclude that ScRad52
is more effective than the human protein in promoting HR,
and at the same time is able to inhibit random integration.
Gene targeting events resemble to DNA repair after DSB
induction. It is common knowledge [for examples see (32,37)]
thatinmammaliancellsRad52bindssingle-strandanddouble-
strand DNA ends, recruits Rad51 and carry out HR. The loca-
tion of this event is identiﬁed with nuclear foci that are seen as
Rad51 positive spots. In these foci, several components of the
recombinationmachinery(RPA, BRCA1and2, Rad50,52 and
54 and others) were demonstrated to converge in a dynamic
series of interactions (25,28,29,38).
Liu and Maizels (29) observed that mouse cells expressing
murine GFP-Rad52 showed an increased number of Rad51
nuclear foci. This prompted us to analyse the distribution
of Rad51 foci in our cells overexpressing ScRad52. To our
surprise, Rad51 foci per cell were reduced, while the number
of focus-positive cells was unaffected.
This ﬁnding can be explained by supposing that ScRad52
can organize DNA repair/recombination structures excluding
endogenous Rad51. In this case, we propose that ScRad52 acts
in a Rad51-independent fashion also in human cells, thereby
promoting homology search and strand invasion leading to HR
at the expense of random integration. The exclusion of Rad51
from the recombination sites would implicate that ScRad52
may also prevent binding of Ku, a complex involved in the
early binding of DNA breaks and in the NHEJ pathway (39),
explaining the reduction of random integration.
In conclusion, we demonstrate that the expression of
ScRad52 protein in human cells results in higher resistance
to DNA damaging agents MMS and X-rays, a marked increase
of HR both as absolute number and frequency relative to
NHEJ. The identiﬁcation of ScRad52 as a tool that drives
HR could be of great impact to develop new strategies
for gene therapy of single gene disorders. Moreover, these
results make ScRad52 a possible ‘recombination enzyme’ to
be used in studies on the mechanism of recombination, and
wherever a permanent disruption of a chromosomal locus is
desired.
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